Patents by Inventor Hoyoung Huh

Hoyoung Huh has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Thailanstatin analogs
    Patent number: 11691982
    Abstract: The invention provides novel cytotoxic compounds and cytotoxic conjugates comprising these cytotoxic compounds and cell-binding agents. More specifically, this invention relates to novel thailanstatin A analogs, useful as cytotoxic small molecule toxins in antibody-drug conjugates (ADCs). The present invention further relates to compositions including these cytotoxic compounds and ADCs, and methods for using these toxins and ADCs to treat pathological conditions including cancer.
    Type: Grant
    Filed: September 11, 2020
    Date of Patent: July 4, 2023
    Assignee: pH Pharma Co., Ltd.
    Inventors: Vasu Jammalamadaka, Sanjeev Satyal, Hoyoung Huh
  • USE OF A NEUTROPHIL ELASTASE INHIBITOR IN LUNG DISEASE
    Publication number: 20220296597
    Abstract: The invention relates to methods for treating chronic lung disease, in particular, alpha-1 antitrypsin deficiency or emphysema resulting from alpha-1 antitrypsin deficiency, with a neutrophil elastase inhibitor. The invention further relates to pharmaceutical compositions comprising a neutrophil elastase inhibitor.
    Type: Application
    Filed: August 21, 2020
    Publication date: September 22, 2022
    Applicant: pH Pharma Co., Ltd.
    Inventors: Sanjeev SATYAL, Hoyoung HUH
  • USE OF NEUTROPHIL ELASTASE INHIBITORS IN LIVER DISEASE
    Publication number: 20210069192
    Abstract: The invention relates to methods for treating chronic liver disease, in particular nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH), with neutrophil elastase inhibitors. The invention further relates to pharmaceutical compositions comprising neutrophil elastase inhibitors.
    Type: Application
    Filed: September 21, 2020
    Publication date: March 11, 2021
    Applicant: pH Pharma Co., Ltd.
    Inventors: Sanjeev SATYAL, Brian ROBERTS, Xueyan WANG, Scott SAVAGE, Hoyoung HUH
  • THAILANSTATIN ANALOGS
    Publication number: 20200407369
    Abstract: The invention provides novel cytotoxic compounds and cytotoxic conjugates comprising these cytotoxic compounds and cell-binding agents. More specifically, this invention relates to novel thailanstatin A analogs, useful as cytotoxic small molecule toxins in antibody-drug conjugates (ADCs). The present invention further relates to compositions including these cytotoxic compounds and ADCs, and methods for using these toxins and ADCs to treat pathological conditions including cancer.
    Type: Application
    Filed: September 11, 2020
    Publication date: December 31, 2020
    Applicant: pH Pharma Co., Ltd.
    Inventors: Vasu JAMMALAMADAKA, Sanjeev SATYAL, Hoyoung HUH
  • Thailanstatin analogs
    Patent number: 10815246
    Abstract: The invention provides novel cytotoxic compounds and cytotoxic conjugates comprising these cytotoxic compounds and cell-binding agents. More specifically, this invention relates to novel thailanstatin A analogs, useful as cytotoxic small molecule toxins in antibody-drug conjugates (ADCs). The present invention further relates to compositions including these cytotoxic compounds and ADCs, and methods for using these toxins and ADCs to treat pathological conditions including cancer.
    Type: Grant
    Filed: April 5, 2019
    Date of Patent: October 27, 2020
    Assignee: pH Pharma Co., Ltd.
    Inventors: Vasu Jammalamadaka, Kimberly Ann Tipton, Sanjeev Satyal, Hoyoung Huh
  • Use of neutrophil elastase inhibitors in liver disease
    Patent number: 10806735
    Abstract: The invention relates to methods for treating chronic liver disease, in particular nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH), with neutrophil elastase inhibitors. The invention further relates to pharmaceutical compositions comprising neutrophil elastase inhibitors.
    Type: Grant
    Filed: April 22, 2019
    Date of Patent: October 20, 2020
    Assignee: pH Pharma Co., Ltd.
    Inventors: Sanjeev Satyal, Brian Roberts, Xueyan Wang, Scott Savage, Hoyoung Huh
  • THAILANSTATIN ANALOGS
    Publication number: 20200216463
    Abstract: The invention provides novel cytotoxic compounds and cytotoxic conjugates comprising these cytotoxic compounds and cell-binding agents. More specifically, this invention relates to novel thailanstatin A analogs, useful as cytotoxic small molecule toxins in antibody-drug conjugates (ADCs). The present invention further relates to compositions including these cytotoxic compounds and ADCs, and methods for using these toxins and ADCs to treat pathological conditions including cancer.
    Type: Application
    Filed: September 19, 2018
    Publication date: July 9, 2020
    Applicant: pH Pharma Co., Ltd.
    Inventors: Vasu JAMMALAMADAKA, Kimberly Ann TIPTON, Sanjeev SATYAL, Hoyoung HUH
  • USE OF NEUTROPHIL ELASTASE INHIBITORS IN LIVER DISEASE
    Publication number: 20190321364
    Abstract: The invention relates to methods for treating chronic liver disease, in particular nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH), with neutrophil elastase inhibitors. The invention further relates to pharmaceutical compositions comprising neutrophil elastase inhibitors.
    Type: Application
    Filed: April 22, 2019
    Publication date: October 24, 2019
    Applicant: pH Pharma Co., Ltd.
    Inventors: Sanjeev Satyal, Brian Roberts, Xueyan Wang, Scott Savage, Hoyoung Huh
  • THAILANSTATIN ANALOGS
    Publication number: 20190233430
    Abstract: The invention provides novel cytotoxic compounds and cytotoxic conjugates comprising these cytotoxic compounds and cell-binding agents. More specifically, this invention relates to novel thailanstatin A analogs, useful as cytotoxic small molecule toxins in antibody-drug conjugates (ADCs). The present invention further relates to compositions including these cytotoxic compounds and ADCs, and methods for using these toxins and ADCs to treat pathological conditions including cancer.
    Type: Application
    Filed: April 5, 2019
    Publication date: August 1, 2019
    Applicant: pH Pharma Co., Ltd.
    Inventors: Vasu Jammalamadaka, Kimberly Ann Tipton, Sanjeev Satyal, Hoyoung Huh
  • Thailanstatin analogs
    Patent number: 10301319
    Abstract: The invention provides novel cytotoxic compounds and cytotoxic conjugates comprising these cytotoxic compounds and cell-binding agents. More specifically, this invention relates to novel thailanstatin A analogs, useful as cytotoxic small molecule toxins in antibody-drug conjugates (ADCs). The present invention further relates to compositions including these cytotoxic compounds and ADCs, and methods for using these toxins and ADCs to treat pathological conditions including cancer.
    Type: Grant
    Filed: September 19, 2018
    Date of Patent: May 28, 2019
    Assignee: pH Pharma Co., Ltd.
    Inventors: Vasu Jammalamadaka, Sanjeev Satyal, Hoyoung Huh
  • THAILANSTATIN ANALOGS
    Publication number: 20190084996
    Abstract: The invention provides novel cytotoxic compounds and cytotoxic conjugates comprising these cytotoxic compounds and cell-binding agents. More specifically, this invention relates to novel thailanstatin A analogs, useful as cytotoxic small molecule toxins in antibody-drug conjugates (ADCs). The present invention further relates to compositions including these cytotoxic compounds and ADCs, and methods for using these toxins and ADCs to treat pathological conditions including cancer.
    Type: Application
    Filed: September 19, 2018
    Publication date: March 21, 2019
    Inventors: Vasu Jammalamadaka, Kimberly Ann Tipton, Sanjeev Satyal, Hoyoung Huh